Literature DB >> 30675008

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Michele Baccarani1, Fausto Castagnetti2, Gabriele Gugliotta2, Gianantonio Rosti2, Simona Soverini2, Ali Albeer3, Markus Pfirrmann3.   

Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30675008     DOI: 10.1038/s41375-018-0341-4

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

Authors:  F van Rhee; A Hochhaus; F Lin; J V Melo; J M Goldman; N C Cross
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

2.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

Authors:  J V Melo
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

3.  Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.

Authors:  R C Quackenbush; G W Reuther; J P Miller; K D Courtney; W S Pear; A M Pendergast
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.

Authors:  Marjan Yaghmaie; Seyed H Ghaffari; Ardashir Ghavamzadeh; Kamran Alimoghaddam; Mohammad Jahani; Seyed-Asadollah Mousavi; Masoud Irvani; Babak Bahar; Isa Bibordi
Journal:  Arch Iran Med       Date:  2008-05       Impact factor: 1.354

5.  The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients.

Authors:  K I Mills; E D MacKenzie; G D Birnie
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

6.  Autoinhibition of Bcr-Abl through its SH3 domain.

Authors:  Kristen M Smith; Rinat Yacobi; Richard A Van Etten
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

  6 in total
  23 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

3.  A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.

Authors:  Xiao-Shuai Zhang; Robert Peter Gale; Mei-Jie Zhang; Xiao-Jun Huang; Qian Jiang
Journal:  Leukemia       Date:  2022-02-22       Impact factor: 12.883

4.  Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.

Authors:  Abhijit Phukan; Prakas Kumar Mandal; Tuphan K Dolai
Journal:  Ann Hematol       Date:  2020-10-06       Impact factor: 3.673

Review 5.  Treatment-free remission in patients with chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Nat Rev Clin Oncol       Date:  2020-05-06       Impact factor: 66.675

Review 6.  When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.

Authors:  Nuno Cerveira; Susana Bizarro; Manuel R Teixeira; José M Mariz
Journal:  Curr Treat Options Oncol       Date:  2021-04-17

7.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 8.  Fusion transcripts: Unexploited vulnerabilities in cancer?

Authors:  Carla Neckles; Soumya Sundara Rajan; Natasha J Caplen
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-08-13       Impact factor: 9.957

Review 9.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Authors:  A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528

10.  Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia.

Authors:  Laura Kearney; Mireille Crampe; Eibhlin Conneally; Janusz Krawczyk; Senthil Kumar; Philip T Murphy; Vitaliy Mykytiv; Mary-Frances Ryan; Stephen E Langabeer
Journal:  Leuk Res Rep       Date:  2020-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.